Thus, targeting pathways that sustain MYC activity, particularly in the context of MEK inhibition, presents a promising therapeutic strategy to exploit this addiction and enhance treatment efficacy in HNSCC. Here, MYC is linked to head and neck squamous cell carcinoma.